Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00790270
Other study ID # SB2003-1234
Secondary ID
Status Completed
Phase Phase 2
First received November 12, 2008
Last updated October 22, 2012
Start date January 2003
Est. completion date January 2004

Study information

Verified date October 2012
Source Stony Brook University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see whether the combination of a muscle relaxant and anti-inflammatory drug is more effective at relieving pain in patients with neck strains or whiplash than either of the two medications alone.


Description:

Muscle relaxants have been used extensively for neck and back pain since muscle spasm is thought to play a role in the cycle of pain and spasm. However, prior studies have conflicting results regarding their additive effect when given in addition to analgesics such as the NSAIDs. Because they have the potential to lead to adverse events their efficacy should be clearly demonstrated before their routine use.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date January 2004
Est. primary completion date January 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- neck pain within 24 hours of injury

Exclusion Criteria:

- Children, allergy or contraindication to any of the study drugs

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cyclobenzaprine
5 mg orally every 8 hours as needed
Ibuprofen
Ibuprofen 400 mg every 8 hours as needed
Ibuprofen plus Cyclobenzaprine
Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed

Locations

Country Name City State
United States Stony Brook University Stony Brook New York

Sponsors (1)

Lead Sponsor Collaborator
Stony Brook University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Daily for 1 week No
Primary Use of Rescue Medications the number of patients taking additional rescue medications beyond the study meds 24 hours No
Secondary Time to Resumption of Work 1 week No
Secondary Resumption of Work or School number of patients resuming regular activity the day following enrollment. next day No